VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
Phase 1/2 Recruiting
23 enrolled
NYMC195
Phase 1 Recruiting
30 enrolled
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Phase 1 Recruiting
48 enrolled
PEEL-224
Phase 1/2 Recruiting
59 enrolled
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Phase 1/2 Recruiting
90 enrolled
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Phase 1/2 Recruiting
104 enrolled
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Phase 1 Recruiting
24 enrolled
Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
Phase 1 Recruiting
24 enrolled
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
Phase 1 Recruiting
50 enrolled
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Phase 2 Recruiting
60 enrolled
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Phase 1/2 Recruiting
27 enrolled
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Phase 1/2 Recruiting
63 enrolled
IMPACT
Phase 1 Recruiting
21 enrolled
SJFAMILY
Recruiting
1,500 enrolled
SABRE
Phase 1 Recruiting
18 enrolled
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Phase 1 Recruiting
25 enrolled
KinLET
Phase 1 Recruiting
20 enrolled
MAST
Recruiting
1,000 enrolled
Indocyanine Green (ICG) Guided Tumor Resection
Phase 1 Recruiting
230 enrolled
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Phase 1 Recruiting
21 enrolled
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
Phase 1 Recruiting
22 enrolled
Flavored, Oral Irinotecan VAL-413 (OrotecanĀ®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Phase 1 Recruiting
20 enrolled
Ivonescimab in the Treatment of Multiple Advanced Tumors
Phase 2 Recruiting
400 enrolled
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
Phase 2 Recruiting
135 enrolled
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Phase 2 Recruiting
86 enrolled
TARGET-RT
Phase NA Recruiting
70 enrolled
Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of First Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study
Phase 2 Recruiting
88 enrolled
AERO-RMS
Recruiting
20 enrolled
A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors.
Phase 3 Recruiting
300 enrolled
Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents
Phase 2 Recruiting
38 enrolled
Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors
Phase 2 Recruiting
100 enrolled
PerVision
Phase 1/2 Recruiting
30 enrolled
Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen
Phase 1/2 Recruiting
82 enrolled
FaR-RMS
Phase 1/2 Recruiting
1,672 enrolled